Updates are available Correction dated 2020-04-27
Click to view Correction: https://doi.org/10.1038/s41587-020-0534-z
-
Authors
Ding, Jiarui
Adiconis, Xian
Simmons, Sean K.
Kowalczyk, Monika S.
Hession, Cynthia C.
Marjanovic, Nemanja D.
Hughes, Travis K.
Wadsworth, Marc H.
Burks, Tyler
Nguyen, Lan T.
Kwon, John Y. H.
Barak, Boaz
Ge, William http://orcid.org/0000-0002-2278-8201
Kedaigle, Amanda J. http://orcid.org/0000-0001-6156-5046
Carroll, Shaina
Li, Shuqiang
Hacohen, Nir
Rozenblatt-Rosen, Orit
Shalek, Alex K. http://orcid.org/0000-0001-5670-8778
Villani, Alexandra-Chloé
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Levin, Joshua Z. http://orcid.org/0000-0002-0170-3598
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (1U19 MH114821, 1U19 MH114821)
Manton Foundation
Klarman Cell Observatory
- License Information
-
More Information
Article History
Received: 7 May 2019
Accepted: 24 February 2020
First Online: 6 April 2020
Change Date: 27 April 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-020-0534-z
Competing interests
: A.R. is a founder and equity holder in Celsius Therapeutics; an equity holder in Immunitas; and an SAB member of Syros Pharmaceuticals, Neogene Therapeutics and Thermo Fisher Scientific. A.K.S. is a founder of, and consultant for, Honeycomb Biotechnologies, Inc., which manufactures Seq-Well peripherals. A.K.S. and A.R. are also named inventors on patents filed by the Broad Institute related to either Drop-seq (A.R. and A.K.S.), DroNc-seq (A.R.) or Seq-Well (A.K.S). The interests of A.K.S. and A.R. were reviewed and are subject to a management plan overseen by their institutions in accordance with their conflict of interest policies. The other authors declare no competing interests.
